



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

### Complete if Known

Application Number	09/936,888
Filing Date	September 12, 2001
First Named Inventor	Douglas E. BRENNEMAN et al.
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	015280-377100US

TECH CENTER 1600/2900

OCT 31 2002

RECEIVED

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,767,240	06-16-1998	Brenneman et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	2	PCT	WO 92/18140	A1	10-29-1992			<input type="checkbox"/>
	3	PCT	WO 96/11948	A1	04-25-1996			<input type="checkbox"/>
	4	PCT	WO 98/35042	A1	08-13-1998			<input type="checkbox"/>

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	5	Bassan, M. et al. "Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide." <i>Journal of Neurochemistry</i> 72:1283-1293 (1999)	
	6	Bassan, M. et al. "VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein." <i>Regulatory Peptides</i> , 71(2):, August 15, 1997.	
	7	Beni-Adani, L. et al. "Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury." Society for Neuroscience, 28 <sup>th</sup> Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> 23(1):1043 (1998).	
	8	Brenneman et al. "Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide." <i>Nature</i> 335:636 (1988).	
	9	Brenneman et al. "N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures" <i>Dev. Brain Res.</i> 51:63 (1990).	
	10	Brenneman, D.C. and Gozes, I. "A Femtomolar-Acting Neuroprotective Peptide." <i>Journal of Clinical Investigation</i> 97:229-230 (1996)	

Examiner Signature	/Olga Chernyshev/	Date Considered	01/25/2010
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1397800 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

### Complete if Known

Application Number	09/936,888
Filing Date	September 12, 2001
First Named Inventor	Douglas E. BRENNEMAN et al.
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	015280-377100US

TECH CENTER 1600/2900

OCT 31 2002

RECEIVED

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	11	Brenneman, D.E. et al. "Activity-Dependent neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides." <i>Journal of Pharmacology and Experimental Therapeutics</i> 285: 619-627 (1998)	
	12	Brenneman, D.E. et al. "Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2): 2250 (1997).	
	13	Davidson, A. et al. "Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2)2250 (1997).	
	14	Dibbern, D.A., Jr. et al. "Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor." <i>Journal of Clinical Investigation</i> 99: 2837-2841 (1997)	
	15	Giladi, E. "Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." <i>Neuroscience Letters</i> Supplement 48 S1-S60, P. S19 (1997).	
	16	Glazner, G.W. et al. "A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2)2249 (1997).	
	17	Glazner, G.W. et al. "Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth." <i>Anat. Embryol.</i> 200:65-71 (1999).	
	18	Gozes I. et al. "Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity." <i>Developmental Brain Research</i> 99:167-175 (1997).	
	19	Gozes, I. and Brenneman, D.E. "Activity-Dependent Neurotrophic Factor (ADNF)." <i>Journal of Molecular Neuroscience</i> 7:235-244 (1996).	

Examiner Signature	/Olga Chernyshev/	Date Considered	01/25/2010
-----------------------	-------------------	--------------------	------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1397800 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

### Complete if Known

Application Number	09/936,888
Filing Date	September 12, 2001
First Named Inventor	Douglas E. BRENNEMAN et al.
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	015280-377100US

TECH CENTER 1600/2900

OCT 31 2002

RECEIVED

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	20	Gozes, I. et al. "A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP). <i>Neuroscience Letters</i> Supplement 48 S1-S60, p. S21 (1997)-	
	21	Gozes, I. et al. "Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease." <i>Journal of Neurobiology</i> 33:329-342 (1997).	
	22	Gozes, I. et al. "Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A Novel VIP Analog for Noninvasive Impotence Treatment." <i>Endocrinology</i> 134: 2125 (1994).	
	23	Gozes, I. et al. "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors." <i>Journal of Pharmacology and Experimental Therapeutics</i> 27:3161-167 (1995).	
	24	Gozes, I. et al. "The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII)." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2):2250 (1997).	
	25	Gozes, I. et al. "Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide." <i>Proc. Natl. Acad. Sci. USA</i> 93:427-432 (1996).	
	26	Gressens, P. et al. "Growth Factor Function of Vasoactive Intestinal Peptide in Whole Cultured Mouse Embryos." <i>Nature</i> 362:155-58 (1993).	
	27	Hannigan, J.H. and Berman, R.F. "Amelioration of Fetal Alcohol-Related Neurodevelopmental Disorders in Rats: Exploring Pharmacological and Environmental Treatments." <i>Neurotoxicol. &amp; Teratol.</i> 22(1):103-111 (2000).	
	28	Hill, J.M. et al. "Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antisera to Activity-Dependent Neurotrophic Factor (ADNF)." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2):2250 (1997).	
	29	Lilling, G. et al. "Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist." <i>Journal of Molecular Neuroscience</i> 5: 231-239 (1995).	

Examiner Signature	/Olga Chernyshev/	Date Considered	01/25/2010
--------------------	-------------------	-----------------	------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1397800 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

## Complete if Known

Application Number	09/936,888
Filing Date	September 12, 2001
First Named Inventor	Douglas E. BRENNEMAN et al.
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	015280-377100US

TECH CENTER 1600/2900

OCT 31 2002

RECEIVED

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	30	Mahato et al. "Development of Targeted Delivery Systems for Nucleic Acid Drugs." <i>J. of Drug Targeting</i> 4(6):337-357 (1997).	
	31	McKune, S.K. et al. "Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS." Society for Neuroscience, 27 <sup>th</sup> Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> 23(2):2249 (1997)	
	32	Nelbock, P. et al. "A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator. <i>Science</i> , 248:1650-1653 (1990).	
	33	Oberdoester, J. et al. "The Effects of Ethanol on Neuronal Cell Death: Implication for the Fetal Alcohol Syndrome." <i>FASEB Journal</i> 12(4):A134 (March 17, 1998).	
	34	Pelsman, A. et al. "In Vitro Degeneration of Down Syndrome neurons is Prevented by Activity-Dependent Neurotrophic Factor-Derived Peptides." Society for Neuroscience, 28 <sup>th</sup> Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> 24:1044 (1998)	
	35	Skolnick, J. and Fetrow, J.S. "Form Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era." <i>Trends in Biotech.</i> 18(1):34-39 (2000).	
	36	Smith, A.E. "Viral Vectors in Gene Therapy." <i>Ann. Rev. Microbiol.</i> 49:807-838 (1995).	
	37	Spinney, L. "New Peptides Prevent Brain Damage." <i>Molecular Medicine Today</i> 5(7):282 (July 1999).	
	38	Spong et al. "Prevention of Fetal Alcohol Syndrome by Novel Peptides." <i>FASEB Journal</i> 13(5):A881.	

Examiner Signature	/Olga Chernyshev/	Date Considered	01/25/2010
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1397800 v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/